Previously, we revealed that theanine, a green tea component, induced phospholipase C (PLC)-b b1 and -g g1, stress-responsible molecules, in primary cultured rat cerebral cortical neurons, suggesting its protective effect on oxidative stress in neurons. In this study, we investigated whether the same favorable effect occurs in vivo. On the oral administration of theanine (10 mmol (1.74 g)/kg, once a day) to rats via gastric intubation for 2 weeks, there was no change in the weight of the body or the cerebral cortex (Cx), cerebellum (Cb), or hippocampus (Hip) in the brain. On assessment of oxidation levels in the brain with thiobarbiturate reactive substances as a marker, the levels were found to be 20% lower in the Cx of theanine-treated rats than in that of control ones. The protein expression levels of PLC-b b1 and -g g1 were significantly increased in the Cx on theanine administration and the same tendency was observed in the Cb, but not the Hip. In addition, the protein expression level of PLC-d d1, which plays an opposite role to the other two isozymes, was not affected in any brain regions on theanine administration. Overall, it was demonstrated that theanine is a safe compound and its repeated oral administration reduces oxidation levels in the brain, especially the Cx, by increasing PLC-b b1 and -g g1 protein expression, suggesting its favorable effect on the brain in vivo.
Extracellular signals are transmitted across cell membranes through a variety of mechanisms that involve second messenger molecules. Phosphoinositide-specific phospholipase C (PLC) catalyzes the hydrolysis of phosphoinositide into diacylglycerol and three inositol phosphates, of which diacylglycerol and inositol 1,4,5-trisphosphate serve as intracellular messengers for protein kinase C activation and intracellular calcium ion mobilization, respectively. [1] [2] [3] [4] Thus, PLC is a key enzyme in the phosphoinositide signal transduction mechanism. Comparison of amino acid sequences has indicated that PLC can be divided into three types (PLCb, -g and -d) and that each type has multiple subtypes. Of the three main classes of PLC isozymes, the physiological roles are best understood for the first two classes. Overexpression of PLC-b1 and -g1 protects cells from oxidative stress-induced death, [5] [6] [7] suggesting that these isozymes might be proliferative factors for the cells. Recently, Mangat et al. suggested that loading oxidative stress to cardiomyocytes by H 2 O 2 induces PLC-g1 expression, and pharmacological inhibition of PLC-g1 under this condition results in increase of the apoptotic cell death, PLC-g1 playing a role in cardiomyocyte survival during oxidative stress. 8) On the other hand, although it has been reported that PLC-d1 accumulates in Alzheimer's disease brains, 9) is overexpressed in neurons treated with excess glutamate 10) and PLC-d1 plays a critical role in tumor necrosis factor receptor-mediated protection against adriamycin-induced cardiac injury, 11) there is little knowledge on its physiological role.
Theanine, g-glutamylethylamide, is a green tea component, and protects neurons from oxidative stress-induced death in vivo and in vitro experimental systems, [12] [13] [14] [15] [16] [17] but the molecular mechanism underlying the neuron protection by theanine has not been fully clarified yet. Previously, we demonstrated that in primary cultured rat cerebral cortical neurons, theanine protects neurons from glutamate-induced oxidative stress by restoring the decreased protein expression levels of PLC-b1 and -g1, and furthermore, treatment of neurons with theanine alone for a week increases the expression of the two PLC isozymes via stimulation of metabotropic glutamate receptor (mGluR) 1 and/or 5, suggesting that theanine might confer oxidative stress resistance to neurons by inducing PLC-b1 and -g1. 18) However, there is no available information as to whether or not the same favorable effect of theanine occurs in vivo.
In this study, therefore, we investigated the levels of oxidation, and PLC-b1, -g1 and -d1 expression in the brains of rats orally administered theanine for 2 weeks.
MATERIALS AND METHODS
Experimental Design Seven-week-old male Wistar rats were purchased from Japan SLC Inc. (Hamamatsu, Japan), and were housed in individual wire cages in a temperatureand humidity-controlled room (25°C and 55% relative humidity) with a 12 h light and dark cycle. All experiments were approved by the Experimental Animal Research Committee of Kyoto Pharmaceutical University, and were performed according to the Guidelines for Animal Experimentation of Kyoto Pharmaceutical University. Theanine was kindly provided by Taiyo Kagaku Co., Ltd. (Yokkaichi, Japan), and the dosing schedule for theanine was 10 mmol (1.74 g)/kg body weight/d for 2 weeks according to the reports of Yokogoshi et al. 19) and Borzelleca et al., 20) who demonstrated there was significant alteration of amino acid concentrations in the brain after a single intragastric administration, but no apparent toxicity on repeated dietary administration for up to 13 weeks. On the administration of theanine to rats, they were randomly divided into two groups, each consisting of 6 rats. A theanine solution (1 mmol/ml of water) or water was administered orally via gastric intubation to rats at the volume of 10 ml/kg body weight once a day for 2 weeks. On completion of the treatment, the overnightfasted rats were exanguinated by decapitation following by flushing out of the blood with 0.9% saline, and then the brains were removed and fractionated into the cerebral cortex (Cx), cerebellum (Cb) and hippocampus (Hip) under ice-cold conditions. Thereafter, after determining the wet weight of each fraction, all samples were stored at Ϫ80°C until assaying.
Preparation of Samples To each sample, 4 volumes wet weight of a 1.15% KCl solution was added, followed by homogenization with a Polytron homogenizer. Aliquots of the obtained homogenates were used for thiobarbiturate (TBA) assay to determine lipid peroxidation levels by measuring malondialdehyde as an index. 21) To obtain samples for the catalase assay, the homogenates were centrifuged at 105000ϫg for 60 min, and then the supernatants were used to measure catalase activity with a commercially available kit (Red Catalase Assay Kit, Amplex ® ; Molecular Probes, OR, U.S.A.). For Western blotting, samples were prepared by the method previously reported. 18) Protein concentrations were determined by the Bradford method 22) with bovine serum albumin as the standard.
Western Blotting Samples were applied to sodium dodecyl sulfate-polyacrylamide gels at 20 mg protein, and Western blots were performed by the method reported previously, 18) and the PLC-b1, PLC-g1 and PLC-d1 proteins were detected using specific antibodies for them (1 : 500; Santa Cruz Biotechnology, CA, U.S.A.), with which the proteins were recognized as 150-, 145-and 85 kDa bands, respectively, and b-actin was detected with a specific antibody (1 : 5000; Sigma, MO, U.S.A.). Horseradish peroxidase-labeled proteins were detected with an enhanced chemiluminescence detection system (Western Lighting TM Chemiluminescence Reagent; PerkinElmer, MA, U.S.A.). Protein bands reacting with the antibodies were detected on X-ray film (RX-U; Fuji Film, Kanagawa, Japan), and the integrated optical density of each band was measured with a scanning densitometer. Each protein expression level was corrected as to the corresponding b-actin one.
Statistical Analysis Comparisons between two or more groups were performed by means of analysis of variance (ANOVA), followed by Fisher's protected LSD test, differences with a p value of 0.05 or less being considered statistically significant.
RESULTS

General Toxicity
To assess the general toxicity of repeated theanine administration, we measured the weight of the body and brain regions of rats (Table 1) . On 2 weeks oral administration of theanine at the dose of 10 mmol/kg, there were no changes in the weight of the body or each brain region, Cx, Cb, or Hip. These results suggested that theanine administered according to the protocol used in this study did not have any apparent adverse effect on rats.
Oxidation Level The brain is known to be a major oxygen consuming organ and to be exposed to high oxygen levels, and so it seems likely that the brain might be exposed to high amounts of reactive oxygen species. Thus, we investigated the effects of theanine on oxidation levels in the rat brain. The TBA reactive substances (TBARS) values in the Cx were 5.56Ϯ1.03 (nϭ6) and 4.61Ϯ0.55 (nϭ6) for the control and theanine-treated groups, respectively, there being an about 20%, but not significant, decreases on theanine administration. In addition, we measured catalase activity to evaluate the alteration of the oxidation levels. As shown in Table  2 , catalase activity was decreased in all the brain regions on theanine administration.
PLC Isozyme Expression Level
In each brain region, PLC-b1, -g1 and -d1 expression was determined at the protein level (Fig. 1) . The PLC-b1 and -g1 expression levels were significantly increased in the Cx in theanine-adminis- 858 Vol. 31, No. 5 tered rats, and the same tendency was observed in the Cb, although the differences were not significant, while there was no alteration at all in the two PLC isozymes in the Hip. As for PLC-d1, in contrast, theanine administration did not have an effect on its expression in any of the brain regions.
DISCUSSION
Our previous study demonstrated that theanine can prevent neuronal death caused by glutamate-induced oxidative stress through restoration of the decreased expression levels of PLC-b1 and -g1, 18) and the same neuroprotective effect was observed in vivo experimental systems. [12] [13] [14] [15] 17) Furthermore, it appeared that one-week treatment with theanine can increase the protein expression of both the PLC isozymes through stimulation of mGluR1 and/or 5, implying that theanine treatment might provide resistance to oxidative stress. 18) In this study, we found that repeated administration of theanine to rats decreased the lipid peroxidation levels expressed as TBARS values, and increased the protein expression levels of PLC-b1 and -g1 in the brain, especially in the Cx. This is the first report that theanine increases protective molecules against oxidative stress and decreases the oxidation levels in the brain. Therefore, it is expected that theanine might have a favorable effect on the brain in vivo.
To assess the oxidation levels in the brain, we also measured catalase activity, which is a well-known H 2 O 2 scavenger. Unexpectedly, catalase activity was decreased by the theanine administration. Of the major enzymatic antioxidants to maintain redox balance, catalase is known to be an oxidative stress responsible molecule, and is indicated to be induced by loading oxidative stress, 23, 24) although controversial results have also been reported and this discrepancy considered to be due to differences in experimental conditions. 25) Considering the aforementioned suggestion that theanine reduced oxidation levels in the brain, we thought that catalase activity might be decreased by the theanine treatment to maintain the redox balance in the oxidative stress-lowered brain. That is to say, it was considered that increased expression of PLC-b1 and -g1 by theanine decreased oxidation levels in the brain and then catalase activity was decreased, because overexpression of the PLC isozymes was reported to confer resistance against oxidative stress to cells.
5-7)
It has been indicated that theanine administered intragastrically is absorbed via a Na ϩ -coupled cotransporter in the brush-border membrane, 26) and that the absorbed theanine is transported into the brain through the blood-brain barrier via a leucine-preferring transport system. 19) Although the distribution of theanine in the brain has not been clarified yet, the present findings imply that theanine might preferably be distributed in the Cx compared to the other regions examined. To address this issue, more detailed investigation is necessary. Theanine has been demonstrated to be able to induce a relaxed state by stimulating the production of alpha waves in humans, 27) and furthermore, research on whether or not theanine can be used as an alternative to methylphenidate for the treatment of PMS (premenstrual syndrome)-related symptoms including sharpening mental acuity and concentration is ongoing. 20) Overall, it is confident that theanine has a favorable effect on the brain, and the present findings might be involved, at least in part, in these effects, in addition to theanine-induced release of dopamine and GABA (g-aminobutyric acid). 20) As for toxicity, we confirmed that 2-week repeated administration of theanine did not have any effect on the weights of the body or three brain regions. Borzelleca et al. revealed that 13-week dietary administration did not cause any macroscopic and microscopic changes in rats. 20) Since in both studies theanine was administered in high doses, which were calculated to be equivalent to 10000 or more cups of green tea, theanine seems to be a very safe compound. This is supported by the findings for PLC-d1, of which the expression was not affected by theanine administration. This was because we previously demonstrated that aberrant accumulation of PLC-d1 is observed in Alzheimer's disease brains, 9) and that severe oxidative stress causes its increased expression in the brain, 28) and we suggested that PLC-d1 might have an opposite role to that of PLC-b1 and -g1 in oxidative stress management. 29) In summary, repeated administration of theanine decreased the lipid peroxidation level, and increased PLC-b1 and -g1 expression in the brain, especially in the Cx, while there was no change in PLC-d1 expression in any brain regions, implying that theanine might protect the brain, especially the Cx, from oxidative stress via induction of these protective molecules against oxidative stress. Therefore, it seems likely that theanine might have a favorable effect on the brain in vivo.
